论文部分内容阅读
英国两所癌症研究慈善机构,癌研究运动(CRC)和帝国癌研究基金会(ICRF),宣布了癌治疗新途径的进展。 CRC与Zeneca药厂(原称ICI)订立了关于用抗体导向的酶药物前体治疗癌症(ADEPT)的协议。ICRF拟提交关于将IL-2基因转移至恶性肿瘤病人的瘤体内的计划。这将是英国对癌症病人进行基因治疗的第一个计划。 Zeneca协议 CRC的研究者,伦敦红十字会医院,Porton城公共卫生实验室服务中心将与Zeneca协作发展ADEPT技术,此项
Two cancer research charities in the United Kingdom, the Cancer Research Campaign (CRC) and the Imperial Cancer Research Foundation (ICRF), announced the development of new approaches to cancer treatment. CRC and Zeneca Pharmaceuticals (formerly ICI) entered into an agreement on the use of antibody-directed enzyme prodrug therapy for cancer (ADEPT). The ICRF plans to submit a plan for the transfer of the IL-2 gene into tumors of patients with malignant tumors. This will be Britain’s first plan for gene therapy for cancer patients. Zeneca Protocol CRC researcher, London Red Cross Hospital, Porton City Public Health Laboratory Service Center will collaborate with Zeneca to develop ADEPT technology.